These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21782241)

  • 1. Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Stein BL; Smith BD
    Leuk Res; 2011 Sep; 35(9):1161-3. PubMed ID: 21782241
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia.
    Caocci G; Atzeni S; Orrù N; Azzena L; Martorana L; Littera R; Ledda A; La Nasa G
    Leukemia; 2008 Nov; 22(11):2127-8. PubMed ID: 18463676
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
    Latagliata R; Breccia M; Castagnetti F; Stagno F; Luciano L; Gozzini A; Ulisciani S; Cavazzini F; Annunziata M; Sorà F; Rossi AR; Pregno P; Montefusco E; Abruzzese E; Crisà E; Musto P; Tiribelli M; Binotto G; Occhini U; Feo C; Vigneri P; Santini V; Fava C; Rosti G; Alimena G
    Leuk Res; 2011 Sep; 35(9):1164-9. PubMed ID: 21705080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?
    Eskazan AE; Soysal T; Erbilgin Y; Ozbek U; Ferhanoglu B
    Leuk Res; 2011 Sep; 35(9):e145-6. PubMed ID: 21605905
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
    Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
    Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
    Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy.
    Eskazan AE; Hatemi İ; Öngören Aydın S; Ar MC; Soysal T
    Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():233. PubMed ID: 25910316
    [No Abstract]   [Full Text] [Related]  

  • 10. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
    Keating GM; Lyseng-Williamson KA; McCormack PL; Keam SJ
    BioDrugs; 2013 Jun; 27(3):275-9. PubMed ID: 23549840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
    Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
    Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib: for some difficult cases of adult leukaemia.
    Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
    [No Abstract]   [Full Text] [Related]  

  • 13. Dasatinib (Sprycel) for CML and Ph + ALL.
    Med Lett Drugs Ther; 2007 Jan; 49(1252):6-7. PubMed ID: 17220814
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib-induced lupus.
    Rea D; Bergeron A; Fieschi C; Bengoufa D; Oksenhendler E; Dombret H
    Lancet; 2008 Aug; 372(9640):713-4. PubMed ID: 18761212
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib and chronic myeloid leukemia: two-year follow-up in eight clinical trials.
    Pavlů J; Marin D
    Clin Lymphoma Myeloma; 2009 Dec; 9(6):417-24. PubMed ID: 19951880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
    Bryant G
    Clin J Oncol Nurs; 2009 Jun; 13(3):316-23. PubMed ID: 19502190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia.
    Stagno F; Vigneri P; Di Raimondo F
    Leuk Res; 2012 Jul; 36(7):803. PubMed ID: 22502918
    [No Abstract]   [Full Text] [Related]  

  • 19. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 20. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
    Li J; Xu G; Yu S; He L; Guo L
    J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.